Latest Insider Transactions at Arri Vent Biopharma, Inc. (AVBP)
This section provides a real-time view of insider transactions for Arri Vent Biopharma, Inc. (AVBP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ArriVent Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ArriVent Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2024
|
Robin La Chapelle Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,566
+4.53%
|
$82,698
$3.35 P/Share
|
|
Jan 30
2024
|
Hillhouse Investment Management, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
555,555
+11.02%
|
$9,999,990
$18.0 P/Share
|
|
Jan 30
2024
|
Hillhouse Investment Management, Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,929,117
+28.69%
|
-
|
|
Jan 30
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+20.76%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
James Healy Director |
BUY
Conversion of derivative security
|
Indirect |
1,252,308
+50.0%
|
-
|
|
Jan 30
2024
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+12.8%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
2,582,884
+38.33%
|
-
|
|
Jan 30
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
444,444
+12.8%
|
$7,999,992
$18.0 P/Share
|
|
Jan 30
2024
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,582,884
+38.33%
|
-
|